SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.

Category: Pharmacology

Category Search

visual bubble
visual bubble
visual bubble
visual bubble

What is the most recent evidence on anticoagulation dosing for patients with COVID-19, specifically prophylactic versus treatment and duration of therapy?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021

Anticoagulation, Coronavirus, COVID-19

Regarding multimodality therapies, specifically steroids, what would you administer to a patient with COVID-19 today? If the patient were on remdesivir, would you continue the remdesivir for the full duration of therapy?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021

Antivirals, Coronavirus, COVID-19

Regarding anticoagulation strategies, is there a role for tissue plasminogen activator (tPA)? If so, what is the indication for it and who would you use it on?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021

Anticoagulation, Coronavirus, COVID-19

Is there any situation in which you would use steroids in the emergency department? If so, would you use dexamethasone, methylprednisolone, or hydrocortisone?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021

Coronavirus, COVID-19

How long is your standard course of dexamethasone and what is the preferred dosing on a medical ward versus the ICU?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 14, 2021

Coronavirus, Corticosteriods, COVID-19

Can you discuss monoclonal antibody use in the hospital setting?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

Coronavirus, COVID-19, Therapies

Can you comment on indications for ivermectin in patients with COVID-19?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

Coronavirus, COVID-19, Therapies

Can you provide some insight on appropriate vasopressor selection and dosing in these patients?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

Coronavirus, COVID-19, Therapies

Is there any difference between baricitinib and tocilizumab? Would you choose one over the other?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

Coronavirus, COVID-19, Therapies

What is the most appropriate broad-spectrum antibiotic for a patient with a superimposed infection while in the hospital with COVID-19?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

Coronavirus, COVID-19, Therapies

Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019

From Critical Care Explorations. In this study, the authors conclude that argatroban, with or without aspirin, is an effective anticoagulation strategy for patients who require venovenous extracorporeal membrane oxygenation support secondary to coronavirus disease 2019.

Anticoagulation, Coronavirus, COVID-19, ECMO

Regarding fluid management, inotropes, and vasopressors in critically ill patients, which drugs are concerning with excessive fluid volume?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

Coronavirus, COVID-19, Supportive Care

When should paralytics be initiated, when should they be weaned off, and how do you decide whether to monitor neuromuscular blockade?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

Coronavirus, COVID-19, Sedation

What suggestions do you have for pharmacists, physician assistants, nurses, and physicians who work in a traditionally non-ICU environment who want to obtain further skills and knowledge to care for critically ill, difficult-to-manage patients?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

Coronavirus, COVID-19, Resource Allocation

When monitoring hospitalized COVID-19 patients, both critically ill and noncritically ill, to prevent Stenotrophomonas or other secondary infections or fungal infections, when should prophylactic antibiotics be administered?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

Coronavirus, COVID-19, Therapies

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines—Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials

From Critical Care Medicine. In this Review Article the authors established a uniform data collection process required to perform an assessment of any agent type using review criteria that were identified and differentially weighted for each agent class,

Coronavirus, COVID-19, Therapies

Critical Impact: COVID-19: Highlights Session 1

This webinar covers highlights from the Critical Impact: Clinical Practice course.

Coronavirus, COVID-19, Hemodynamic Support, Therapies, Ventilatory Support

FDA Resource: Molnupiravir received EUA approval from the FDA

The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir should only be used when other COVID-19 treatments are unavailable. 

Coronavirus, COVID-19, Therapies

FDA Resource: Paxlovid received EUA approval from the FDA

December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Coronavirus, COVID-19, Therapies

WHO Resource: WHO Therapeutics and COVID-19: living guideline

The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.

Coronavirus, COVID-19, Therapies